{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:50:46Z","timestamp":1791399046872,"version":"4.3.3"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Advanced or metastatic cervical cancer has a poor prognosis, and the 5-year overall survival is &amp;lt;5% with conventional radiotherapy and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), achieved initial success in advanced solid tumors, while their efficacy and safety in advanced or metastatic cervical cancer remains to be explored. Previous studies found high-risk HPV infection and elevated PD-L1 expression in cervical precancerous lesions and squamous cell carcinoma. Meanwhile, elevated PD-L1 expression, high cytotoxic T lymphocyte infiltration, and abnormal cytotoxic T lymphocyte function might benefit inflammation infiltration for ICIs in the tumor microenvironment. Patients with HPV infection, squamous cell carcinoma, advanced stage, large tumor size, poor differentiation, metastatic disease, history of multiple childbirth and abortion, or a previous history of receiving chemotherapy might be associated with positive PD-L1 expression. Although there is no correlation between PD-L1 expression and prognosis using conventional radiotherapy, patients with high PD-L1 expression have a poorer prognosis. Several clinical studies demonstrate preliminary safety and efficacy for PD-1\/PD-L1 inhibitors, and the exploration of combination strategies such as immunotherapy combined with chemotherapy, radiotherapy, anti-angiogenesis therapy, or dual ICIs is ongoing. This paper systematically reviews PD-L1 expression patterns and their relationship with prognosis, along with reported and ongoing clinical trials of PD-1\/PD-L1 inhibitors in cervical cancer to clarify the prospect of ICIs for cervical cancer from bench to bed.<\/jats:p>","DOI":"10.3389\/fonc.2022.849352","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:17:27Z","timestamp":1665728247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["PD-1\/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed"],"prefix":"10.3389","volume":"12","author":[{"given":"Weijia","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-017-9178-6_7","article-title":"The human development index: Objective approaches (2)","volume-title":"Global handbook of quality of life: Exploration of well-being of nations and continents","author":"Land","year":"2015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr015","article-title":"Worldwide burden of cervical cancer in 2008","volume":"22","author":"Arbyn","year":"2011","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/AOG.0000000000003311","article-title":"Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines","volume":"134","author":"Wright","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajog.2015.07.022","article-title":"Changing paradigms in the systemic treatment of advanced cervical cancer","volume":"214","author":"Pfaendler","year":"2016","journal-title":"Am J obstet gynecol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21565","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA: Cancer J Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)02250-2","article-title":"Randomised study of radical surgery versus radiotherapy for stage ib-IIa cervical cancer","volume":"350","author":"Landoni","year":"1997","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001506","article-title":"Loss of MHC class I expression in HPV-associated cervical and vulvar neoplasia: A potential mechanism of resistance to checkpoint inhibition","volume":"44","author":"Dibbern","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6891482","DOI":"10.1155\/2016\/6891482","article-title":"Elevated expression of programmed death-1 and programmed death ligand-1 negatively regulates immune response against cervical cancer cells","volume":"2016","author":"Chen","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Modern Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.5292","article-title":"Clinical cancer advances 2017: Annual report on progress against cancer from the American society of clinical oncology","volume":"35","author":"Burstein","year":"2017","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced Non\u2212Small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: An evidence-based review on the emerging new data","volume":"11","author":"du Rusquec","year":"2019","journal-title":"Cancer Manage Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: Results from the phase ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.034","article-title":"Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528\/NRG-GY002)","author":"Santin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e001126","DOI":"10.1136\/jitc-2020-001126","article-title":"Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer","volume":"8","author":"Friedman","year":"2020","journal-title":"J immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02140","article-title":"Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against triple negative breast cancer cells","volume":"9","author":"Julia","year":"2018","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ygyno.2015.12.030","article-title":"Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine","volume":"141","author":"Zamarin","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpor.2018.05.001","article-title":"The current status of immunotherapy for cervical cancer","volume":"23","author":"Orbegoso","year":"2018","journal-title":"Rep Pract Oncol radiother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0222","article-title":"Late-stage tumor regression after PD-L1 blockade plus a concurrent OX40 agonist","volume":"7","author":"Polesso","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-018-0593-2","article-title":"The role of PD-1 checkpoint inhibition in gynecologic malignancies","volume":"19","author":"Garcia","year":"2018","journal-title":"Curr Treat options Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human b-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2797","article-title":"Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma","volume":"20","author":"Atefi","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.3390\/ijms20133310","article-title":"The formation and therapeutic update of tumor-associated macrophages in cervical cancer","volume":"20","author":"Wang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.846786","article-title":"Identification of novel tumor microenvironment regulating factor that facilitates tumor immune infiltration in cervical cancer","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e142513","DOI":"10.1172\/jci.insight.142513","article-title":"PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells","volume":"6","author":"Balan\u00e7a","year":"2021","journal-title":"JCI Insight"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.7150\/thno.21471","article-title":"Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: Immunotherapeutic implications","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/v7072802","article-title":"Human papillomaviruses; epithelial tropisms, and the development of neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2016.27.e21","article-title":"Clinical significance of human papillomavirus genotyping","volume":"27","author":"Choi","year":"2016","journal-title":"J gynecol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00546.x","article-title":"Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins","volume":"98","author":"Narisawa-Saito","year":"2007","journal-title":"Cancer Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0023","article-title":"Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene","volume":"69","author":"Jabbar","year":"2009","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.7.3159","article-title":"Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity","volume":"89","author":"Romanczuk","year":"1992","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PD\u2212L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7150\/jca.22532","article-title":"PD-L1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer","volume":"9","author":"Meng","year":"2018","journal-title":"J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13411","article-title":"Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status","volume":"43","author":"Yang","year":"2017","journal-title":"J obstet gynaecol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007270","article-title":"Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients","volume":"96","author":"Yang-Chun","year":"2017","journal-title":"Medicine"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-018-0674-4","article-title":"PD-1\/PD-L1 blockade in cervical cancer: current studies and perspectives","volume":"13","author":"Wang","year":"2019","journal-title":"Front Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1128\/jvi.62.1.84-90.1988","article-title":"Accumulation of RNA homologous to human papillomavirus type 16 open reading frames in genital precancers","volume":"62","author":"Crum","year":"1988","journal-title":"J Virol"},{"key":"B51","article-title":"Nonradioactive RNA in situ hybridization detection of human papillomavirus 16-E7 transcripts in squamous cell carcinomas of the uterine cervix using confocal laser scan microscopy","volume":"139","author":"van den Brule","year":"1991","journal-title":"Am J Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0163","article-title":"Human papilloma virus specific immunogenicity and dysfunction of CD8(+) T cells in head and neck cancer","volume":"78","author":"Krishna","year":"2018","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12101","article-title":"Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia","volume":"139","author":"Yang","year":"2013","journal-title":"Immunology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","article-title":"PD-L1 testing for lung cancer in 2019: Perspective from the IASLC pathology committee","volume":"15","author":"Lantuejoul","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.01.514","article-title":"PD-1, PD-L1 expression in 1599 gynecological cancers: Implications for immunotherapy","volume":"137","author":"Arguello","year":"2015","journal-title":"Gynecol Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S152232","article-title":"The relationship between the PD-1\/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance","volume":"10","author":"Feng","year":"2018","journal-title":"Cancer Manage Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S194597","article-title":"Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression","volume":"11","author":"Grochot","year":"2019","journal-title":"Cancer Manage Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn Pathol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Modern Pathol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000623","article-title":"PD-L1 expression correlates with young age and CD8+ TIL density in poorly differentiated cervical squamous cell carcinoma","volume":"39","author":"Saglam","year":"2020","journal-title":"Int J gynecol Pathol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"Karim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.7150\/jca.34793","article-title":"Consistency analysis of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer: A retrospective study","volume":"11","author":"Luo","year":"2020","journal-title":"J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1159\/000515441","article-title":"Spatial intratumoral heterogeneity expression of PD-L1 antigen in head and neck squamous cell carcinoma","volume":"99","author":"Hirshoren","year":"2021","journal-title":"Oncology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0119","article-title":"Pembrolizumab in recurrent advanced cervical squamous carcinoma","volume":"9","author":"Martinez","year":"2017","journal-title":"Immunotherapy"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26769","article-title":"Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer","volume":"10","author":"Madeddu","year":"2019","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33136","article-title":"Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer","volume":"126","author":"Duska","year":"2020","journal-title":"Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30486-1","article-title":"Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial","volume":"21","author":"Youn","year":"2020","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-Positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.018","article-title":"Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and\/or metastatic cervical cancer","volume":"163","author":"O\u2019Malley","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02067","article-title":"Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: An open-label phase II study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"New Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5676-3","article-title":"PRIMMO study protocol: A phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer","volume":"19","author":"Tuyaerts","year":"2019","journal-title":"BMC Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-018-4764-0","article-title":"\u2019DURVIT\u2019: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: Safety, toxicity and effect on the primary tumour- and lymph node microenvironment","volume":"18","author":"Rotman","year":"2018","journal-title":"BMC Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2609","article-title":"First-In-Human study of cemiplimab alone or in combination with radiotherapy and\/or low-dose cyclophosphamide in patients with advanced malignancies","volume":"26","author":"Papadopoulos","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.849352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:17:32Z","timestamp":1665728252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.849352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":80,"alternative-id":["10.3389\/fonc.2022.849352"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.849352","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"849352"}}